Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Table 4 Oral corticosteroid (OCS) reduction in OCS-dependent patients receiving benralizumab treatment at 1 year of follow-up

	Baseline	1-year FUP
Corticosteroid (CS)-dependent patients, n/N (%)	53/182 (29.1%)	25/200 (12.5%)
Daily OCS dose (mg), mean (SD)	19.7 (15.8)	5.8 (9.4)
Daily OCS dose (mg), median [Q1-Q3]	15 [6.3–29.0]	0.0 [0.0-8.3]
Change in OCS use
Patients achieving an OCS dose reduction ≥ 50%, n/N (%)		33/53 (62.3%)
Patients achieving complete OCS withdrawal, n/N (%)		28/53 (52.8%)
Percentage reduction in mean daily OCS dose		70.4%
Percentage reduction in median daily OCS dose		100.0%

Corticosteroid-dependent patients were defined as those who received maintenance systemic corticosteroid treatment for at least 3 months, within the 12 months prior to the index date
CS, corticosteroids; FUP, follow-up; quartiles 1 and 3 (Q1-Q3); OCS, oral corticosteroids; SD, standard deviation

ISSN: 1465-993X